Merrill Lynch analyst Kevin Fischbeck reiterated a Buy rating on Centene (NYSE:CNC) on Tuesday, setting a price target of $75, which is approximately 13.64% above the present share price of $66.
Fischbeck expects Centene to post earnings per share (EPS) of -$0.02 for the second quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Centene, with an average price target of $76.
The analysts price targets range from a high of $90 to a low of $65.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $28.29 billion and a net profit of $15 million. The company's market cap is $38.39 billion.
According to TipRanks.com, Merrill Lynch analyst Kevin Fischbeck is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 10.8% and a 70.00% success rate.
Centene Corporation is a diversified healthcare company that primarily engages in providing programs and services to the government sponsored healthcare programs. The company is also engaged in providing education and outreach programs to assist members in accessing quality and appropriate healthcare services.